Coverage
Filings
| Filing | Date |
|---|---|
| Transaction in Own Shares | 7 Aug 2009 |
| Half-yearly report | 6 Aug 2009 |
| Transaction in Own Shares | 3 Aug 2009 |
| Transaction in Own Shares | 27 Jul 2009 |
| Transaction in Own Shares | 20 Jul 2009 |
| Transaction in Own Shares | 13 Jul 2009 |
| Transaction in Own Shares | 6 Jul 2009 |
| Regulatory Approval | 3 Jul 2009 |
| Treasury Stock |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 1 Jul 2009 |
| Total voting rights | 30 Jun 2009 |
| Transaction in Own Shares | 29 Jun 2009 |
| Novo Nordisk insulin analogues have proven safety profiles | 28 Jun 2009 |